Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Remegen (9995 HK): New Licensing Deal With AbbVie Brings $650M Upfront Cash

Remegen (9995 HK): 2H25 Upfront Boost; Indication Expansion Positive; Overseas Trial Results Awaited

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/remegen-co-ltd-class-h" target="_blank" data-smartkarma-citation="entities:29191:1" rel="noopener">RemeGen (9995 HK)</a> received marketing approval from NMPA fot the indications of IgA nephropathy and Sjögren’s Disease.</li>
<li>Otsuka’s Voyxact posted positive Phase 3 results for treatment of IgA nephropathy. Telitacicept happen to have an edge in terms of dual inhibitor capability and extent of reduction of proteinuria.</li>
<li>In 2025, Remegen has successfully posted profit on the back of accelerating revenue, improved margins and decelerating expenses. Approval of telitacicept for more indications will help boost revenues further.</li>
</ul>



RemeGen (9995 HK) received marketing approval from NMPA fot the indications of IgA nephropathy and Sjögren’s Disease.
Otsuka’s Voyxact posted positive Phase 3 results for treatment of IgA nephropathy. Telitacicept happen to have an edge in terms of dual inhibitor capability and extent of reduction of proteinuria.
In 2025, Remegen has successfully posted profit on the back of accelerating revenue, improved margins and decelerating expenses. Approval of telitacicept for more indications will help boost revenues further.


RemeGen (9995 HK): Telitacicept Approval For More Indications A Positive